MicroRNA-19 triggers epithelial-mesenchymal transition of lung cancer cells accompanied by growth inhibition

Laboratory Investigation

Volumn 95, Issue 9, 2015, Pages 1056-1070

  Li, Jing ^a,b   Yang, Sheng ^a   Yan, Wen ^a,c   Yang, Jie ^a   Qin, Yu Juan ^a   Lin, Xiao Lin ^a   Xie, Rao Ying ^a   Wang, Sheng Chun ^a   Jin, Wen ^c   Gao, Fei ^a   Shi, Jun Wen ^a   Zhao, Wen Tao ^a   Jia, Jun Shuang ^a   Shen, Hong Fen ^a   Ke, Jie Rong ^a   Liu, Bin ^a   Zhao, Yi Qiao ^c   Huang, Wen Hua ^a   Yao, Kai Tai ^a   Li, Dan Juan ^a   Xiao, Dong ^a   more..

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b FIRST HOSPITAL OF SHIJIAZHUANG   (China)

^c GUANGDONG SECOND PROVINCIAL GENERAL HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA CATENIN; CASPASE 3; CASPASE 8; FIBRONECTIN; INHIBITOR OF DIFFERENTIATION 2; INTERSTITIAL COLLAGENASE; LPAR1 PROTEIN; MICRORNA; MICRORNA 19; MICRORNA 19A; MICRORNA 19B 1; NERVE CELL ADHESION MOLECULE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE 3 KINASE; PLATELET DERIVED GROWTH FACTOR ALPHA; PROTEIN; PROTEIN KINASE B; PROTEIN ZO1; SMALL INTERFERING RNA; SOMATOMEDIN BINDING PROTEIN; STROMELYSIN 2; TRANSCRIPTION FACTOR E2F; TRANSCRIPTION FACTOR TWIST; TRANSCRIPTION FACTOR TWIST 1; TRANSCRIPTION FACTOR TWIST 2; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA2; UNCLASSIFIED DRUG; UVOMORULIN; VIMENTIN; CADHERIN; CDH2 PROTEIN, HUMAN; FN1 PROTEIN, HUMAN; LEUKOCYTE ANTIGEN; LUCIFERASE; MIRN19 MICRORNA, HUMAN; SNAIL FAMILY TRANSCRIPTION FACTORS; TETRAZOLIUM; THIAZOLE DERIVATIVE; THIAZOLYL BLUE; TJP1 PROTEIN, HUMAN; TRANSCRIPTION FACTOR;

A549 CELL LINE; ACTIN CAPPING; ACTIN FILAMENT; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL ADHESION; CELL INVASION; CELL MIGRATION; CELL MOTILITY; CELL PROLIFERATION ASSAY; COLONY FORMATION; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVITY; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; FOCAL ADHESION; G1 PHASE CELL CYCLE CHECKPOINT; GAP JUNCTION; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; LUNG CANCER; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RANDOMIZED CONTROLLED TRIAL; RNA INTERFERENCE; STRESS FIBER; TIGHT JUNCTION; TRANSIENT TRANSFECTION; TUMOR INVASION; UPREGULATION; ANIMAL; BAGG ALBINO MOUSE; DNA MICROARRAY; DRUG EFFECTS; DRUG SCREENING; GENE EXPRESSION REGULATION; LUNG TUMOR; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; TUMOR CELL LINE; WESTERN BLOTTING;

ALPHA CATENIN; ANIMALS; ANTIGENS, CD; BLOTTING, WESTERN; CADHERINS; CELL ADHESION; CELL LINE, TUMOR; EPITHELIAL-MESENCHYMAL TRANSITION; FIBRONECTINS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUCIFERASES; LUNG NEOPLASMS; MICE; MICE, INBRED BALB C; MICRORNAS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RNA INTERFERENCE; TETRAZOLIUM SALTS; THIAZOLES; TRANSCRIPTION FACTORS; TUMOR STEM CELL ASSAY; VIMENTIN; ZONULA OCCLUDENS-1 PROTEIN;

EID: 84940389448     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.2015.76     Document Type: Article

References (67)

1. Croce CM. Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet. 2009; 10: 704-714.
2. Garzon R, Calin GA, Croce CM. MicroRNAs in cancer. Annu Rev Med. 2009; 60: 167-179.
3. Mendell JT. miRiad roles for the miR-17-92 cluster in development and disease. Cell. 2008; 133: 217-222.
4. Olive V, Jiang I, He L. mir-17-92, a cluster of miRNAs in the midst of the cancer network. Int J Biochem Cell Biol. 2010; 42: 1348-1354.
5. van Haaften G, Agami R. Tumorigenicity of the miR-17-92 cluster distilled. Genes Dev. 2010; 24: 1-4.
6. Hayashita Y, Osada H, Tatematsu Y., et al. A polycistronic microRNA cluster, miR-17-92, is overexpressed in human lung cancers and enhances cell proliferation. Cancer Res. 2005; 65: 9628-9632.
7. Liu M, Wang Z, Yang S., et al. TNF-Alpha is a novel target of miR-19a. Int J Oncol. 2011; 38: 1013-1022.
8. Connolly E, Melegari M, Landgraf P., et al. Elevated expression of the miR-17-92 polycistron and miR-21 in hepadnavirus-Associated hepatocellular carcinoma contributes to the malignant phenotype. Am J Pathol. 2008; 173: 856-864.
9. Sang L, Roberts JM, Coller HA. Hijacking HES1: how tumors co-opt the anti-differentiation strategies of quiescent cells. Trends Mol Med. 2010; 16: 17-26.
10. Olive V, Bennett MJ, Walker JC., et al. miR-19 is a key oncogenic component of mir-17-92. Genes Dev. 2009; 23: 2839-2849.
11. Navarro A, Marrades RM, Vinolas N., et al. MicroRNAs expressed during lung cancer development are expressed in human pseudoglandular lung embryogenesis. Oncology. 2009; 76: 162-169.
12. Wu C, Cao Y, He Z., et al. Serum levels of miR-19b and miR-146a as prognostic biomarkers for non-small cell lung cancer. Tohoku J Exp Med. 2014; 232: 85-95.
13. Lin Q, Chen T, Lin Q., et al. Serum miR-19a expression correlates with worse prognosis of patients with non-small cell lung cancer. J Surg Oncol. 2013; 107: 767-771.
14. Wu Q, Yang Z, An Y., et al. MiR-19a/b modulate the metastasis of gastric cancer cells by targeting the tumour suppressor MXD1. Cell Death Dis. 2014; 5: e1144.
15. Xu XL, Jiang YH, Feng JG., et al. MicroRNA-17, microRNA-18a, and microRNA-19a are prognostic indicators in esophageal squamous cell carcinoma. Ann Thorac Surg. 2014; 97: 1037-1045.
16. Zhang J, Xiao Z, Lai D., et al. miR-21, miR-17 and miR-19a induced by phosphatase of regenerating liver-3 promote the proliferation and metastasis of colon cancer. Br J Cancer. 2012; 107: 352-359.
17. Xu XM, Wang XB, Chen MM., et al. MicroRNA-19a and -19b regulate cervical carcinoma cell proliferation and invasion by targeting CUL5. Cancer Lett. 2012; 322: 148-158.
18. Fan Y, Yin S, Hao Y., et al. miR-19b promotes tumor growth and metastasis via targeting TP53. RNA. 2014; 20: 765-772.
19. Thiery JP, Sleeman JP. Complex networks orchestrate epithelialmesenchymal transitions. Nat Rev Mol Cell Biol. 2006; 7: 131-142.
20. Christofori G. New signals from the invasive front. Nature. 2006; 441: 444-450.
21. Shan SW, Lee DY, Deng Z., et al. MicroRNA MiR-17 retards tissue growth and represses fibronectin expression. Nat Cell Biol. 2009; 11: 1031-1038.
22. Larue L, Bellacosa A. Epithelial-mesenchymal transition in development and cancer: role of phosphatidylinositol 3' kinase/AKT pathways. Oncogene. 2005; 24: 7443-7454.
23. Bakin AV, Tomlinson AK, Bhowmick NA., et al. Phosphatidylinositol 3-kinase function is required for transforming growth factor betamediated epithelial to mesenchymal transition and cell migration. J Biol Chem. 2000; 275: 36803-36810.
24. Liu RY, Zeng Y, Lei Z., et al. JAK/STAT3 signaling is required for TGFbeta-induced epithelial-mesenchymal transition in lung cancer cells. Int J Oncol. 2014; 44: 1643-1651.
25. Cho KH, Jeong KJ, Shin SC., et al. STAT3 mediates TGF-beta1-induced TWIST1 expression and prostate cancer invasion. Cancer Lett. 2013; 336: 167-173.
26. Hu QD, Chen W, Yan TL., et al. NSC 74859 enhances doxorubicin cytotoxicity via inhibition of epithelial-mesenchymal transition in hepatocellular carcinoma cells. Cancer Lett. 2012; 325: 207-213.
27. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest. 2009; 119: 1420-1428.
28. Yilmaz M, Christofori G. EMT, the cytoskeleton, and cancer cell invasion. Cancer Metastasis Rev. 2009; 28: 15-33.
29. Mu P, Han YC, Betel D., et al. Genetic dissection of the miR-17 ~ 92 cluster of microRNAs in Myc-induced B-cell lymphomas. Genes Dev. 2009; 23: 2806-2811.
30. Barrallo-Gimeno A, Nieto MA. The Snail genes as inducers of cell movement and survival: implications in development and cancer. Development. 2005; 132: 3151-3161.
31. Browne G, Sayan AE, Tulchinsky E. ZEB proteins link cell motility with cell cycle control and cell survival in cancer. Cell Cycle. 2010; 9: 886-891.
32. Evdokimova V, Tognon C, Ng T., et al. Reduced proliferation and enhanced migration: two sides of the same coin? Molecular mechanisms of metastatic progression by YB-1. Cell Cycle. 2009; 8: 2901-2906.
33. Schickel R, Park SM, Murmann AE., et al. miR-200c regulates induction of apoptosis through CD95 by targeting FAP-1. Mol Cell. 2010; 38: 908-915.
34. Vega S, Morales AV, Ocana OH., et al. Snail blocks the cell cycle and confers resistance to cell death. Genes Dev. 2004; 18: 1131-1143.
35. Zhang X, Yu H, Lou JR., et al. MicroRNA-19 (miR-19) regulates tissue factor expression in breast cancer cells. J Biol Chem. 2011; 286: 1429-1435.
36. Huang G, Nishimoto K, Zhou Z., et al. miR-20a encoded by the miR-17-92 cluster increases the metastatic potential of osteosarcoma cells by regulating Fas expression. Cancer Res. 2012; 72: 908-916.
37. Zhao X, Lu Y, Nie Y., et al. MicroRNAs as critical regulators involved in regulating epithelial- mesenchymal transition. Curr Cancer Drug Targets. 2013; 13: 935-944.
38. Sreekumar R, Sayan BS, Mirnezami AH., et al. MicroRNA control of invasion and metastasis pathways. Front Genet. 2011; 2: 58.
39. Polyak K, Weinberg RA. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer. 2009; 9: 265-273.
40. Nicoloso MS, Spizzo R, Shimizu M., et al. MicroRNAs-The micro steering wheel of tumour metastases. Nat Rev Cancer. 2009; 9: 293-302.
41. Bullock MD, Sayan AE, Packham GK., et al. MicroRNAs: critical regulators of epithelial to mesenchymal (EMT) and mesenchymal to epithelial transition (MET) in cancer progression. Biol Cell. 2012; 104: 3-12.
42. Zhang JG, Wang JJ, Zhao F., et al. MicroRNA-21 (miR-21) represses tumor suppressor PTEN and promotes growth and invasion in nonsmall cell lung cancer (NSCLC). Clin Chim Acta. 2010; 411: 846-852.
43. Yang Y, Ahn YH, Gibbons DL., et al. The Notch ligand Jagged2 promotes lung adenocarcinoma metastasis through a miR-200-dependent pathway in mice. J Clin Invest. 2011; 121: 1373-1385.
44. Kumarswamy R, Mudduluru G, Ceppi P., et al. MicroRNA-30a inhibits epithelial-To-mesenchymal transition by targeting Snai1 and is downregulated in non-small cell lung cancer. Int J Cancer. 2012; 130: 2044-2053.
45. Du L, Pertsemlidis A. microRNAs and lung cancer: tumors and 22-mers. Cancer Metastasis Rev. 2010; 29: 109-122.
46. Cherni I, Weiss GJ. miRNAs in lung cancer: large roles for small players. Future Oncol. 2011; 7: 1045-1055.
47. Arora S, Ranade AR, Tran NL., et al. MicroRNA-328 is associated with (non-small) cell lung cancer (NSCLC) brain metastasis and mediates NSCLC migration. Int J Cancer. 2011; 129: 2621-2631.
48. Zheng F, Liao YJ, Cai MY., et al. The putative tumour suppressor microRNA-124 modulates hepatocellular carcinoma cell aggressiveness by repressing ROCK2 and EZH2. Gut. 2012; 61: 278-289.
49. Abate-Shen C, Banach-Petrosky WA, Sun X., et al. Nkx3.1; Pten mutant mice develop invasive prostate adenocarcinoma and lymph node metastases. Cancer Res. 2003; 63: 3886-3890.
50. Akca H, Demiray A, Tokgun O., et al. Invasiveness and anchorage independent growth ability augmented by PTEN inactivation through the PI3K/AKT/NFkB pathway in lung cancer cells. Lung cancer. 2011; 73: 302-309.
51. Chung MJ, Jung SH, Lee BJ., et al. Inactivation of the PTEN gene protein product is associated with the invasiveness and metastasis, but not angiogenesis, of breast cancer. Pathol Int. 2004; 54: 10-15.
52. Damsky WE, Curley DP, Santhanakrishnan M., et al. β-Catenin signaling controls metastasis in Braf-Activated Pten-deficient melanomas. Cancer Cell. 2011; 20: 741-754.
53. Dankort D, Curley DP, Cartlidge RA., et al. Braf(V600E) cooperates with Pten loss to induce metastatic melanoma. Nat Genet. 2009; 41: 544-552.
54. Ratnacaram CK, Teletin M, Jiang M., et al. Temporally controlled ablation of PTEN in adult mouse prostate epithelium generates a model of invasive prostatic adenocarcinoma. Proc Natl Acad Sci USA. 2008; 105: 2521-2526.
55. Sawai H, Yasuda A, Ochi N., et al. Loss of PTEN expression is associated with colorectal cancer liver metastasis and poor patient survival. BMC Gastroenterol. 2008; 8: 56.
56. Shih MC, Chen JY, Wu YC., et al. TOPK/PBK promotes cell migration via modulation of the PI3K/PTEN/AKT pathway and is associated with poor prognosis in lung cancer. Oncogene. 2012; 31: 2389-2400.
57. Sze KM, Wong KL, Chu GK., et al. Loss of phosphatase and tensin homolog enhances cell invasion and migration through AKT/Sp-1 transcription factor/matrix metalloproteinase 2 activation in hepatocellular carcinoma and has clinicopathologic significance. Hepatology. 2011; 53: 1558-1569.
58. Liang Z, Li Y, Huang K., et al. Regulation of miR-19 to breast cancer chemoresistance through targeting PTEN. Pharm Res. 2011; 28: 3091-3100.
59. Wang F, Li T, Zhang B., et al. MicroRNA-19a/b regulates multidrug resistance in human gastric cancer cells by targeting PTEN. Biochem Biophys Res Commun. 2013; 434: 688-694.
60. Bowen KA, Doan HQ, Zhou BP., et al. PTEN loss induces epithelial- mesenchymal transition in human colon cancer cells. Anticancer Res. 2009; 29: 4439-4449.
61. Mulholland DJ, Kobayashi N, Ruscetti M., et al. Pten loss and RAS/MAPK activation cooperate to promote EMT and metastasis initiated from prostate cancer stem/progenitor cells. Cancer Res. 2012; 72: 1878-1889.
62. Wang H, Quah SY, Dong JM., et al. PRL-3 down-regulates PTEN expression and signals through PI3K to promote epithelial-mesenchymal transition. Cancer Res. 2007; 67: 2922-2926.
63. Song LB, Li J, Liao WT., et al. The polycomb group protein Bmi-1 represses the tumor suppressor PTEN and induces epithelial-mesenchymal transition in human nasopharyngeal epithelial cells. J Clin Invest. 2009; 119: 3626-3636.
64. Evdokimova V, Tognon C, Ng T., et al. Translational activation of snail1 and other developmentally regulated transcription factors by YB-1 promotes an epithelial-mesenchymal transition. Cancer Cell. 2009; 15: 402-415.
65. Mejlvang J, Kriajevska M, Vandewalle C., et al. Direct repression of cyclin D1 by SIP1 attenuates cell cycle progression in cells undergoing an epithelial mesenchymal transition. Mol Biol Cell. 2007; 18: 4615-4624.
66. Franco DL, Mainez J, Vega S., et al. Snail1 suppresses TGF-beta-induced apoptosis and is sufficient to trigger EMT in hepatocytes. J Cell Sci. 2010; 123(Pt 20): 3467-3477.
67. Sayan AE, Griffiths TR, Pal R., et al. SIP1 protein protects cells from DNA damage-induced apoptosis and has independent prognostic value in bladder cancer. Proc Natl Acad Sci USA. 2009; 106: 14884-14889.